Association Between Family History of Malignant Neoplasms and Clinicopathological Features of Breast Cancer Patients
-
摘要:目的
探讨恶性肿瘤家族史(MN-FH)与乳腺癌患者临床病理特征之间的关系。
方法回顾性分析东南大学附属中大医院2016年1月—2018年12月收治的417例乳腺癌患者的临床病理资料，根据有无MN-FH分成两组。采用χ2检验分析两组患者临床病理特征之间的关系。
结果417例乳腺癌患者中，有MN-FH者67例(16.1%)。有MN-FH组的患者有更高比例的脉管癌栓(P=0.046)和淋巴结转移(P=0.023)，肿瘤更易表现为ER阴性(P=0.025)、PR阴性(P=0.031)和HER2阳性(P=0.041)。进一步亚组分析发现，有乳腺癌家族史的患者较无MN-FH的患者有更晚的肿瘤分期(P=0.011)，肿瘤更易表现为三阴性和HER2扩增型(P=0.010)。其他恶性肿瘤家族史的患者较无MN-FH的患者有更高比例的脉管癌栓(P=0.036)和淋巴结转移(P=0.034)。
结论有MN-FH的乳腺癌患者肿瘤恶性程度更高，对于有MN-FH的人群体检非常重要。
Abstract:ObjectiveTo investigate the association between family history of malignant neoplasms (MN-FH) and clinicopathological characteristics of patients with breast cancer.
MethodsWe analyzed retrospectively the clinical data of 417 breast cancer patients in Zhong Da Hospital from January 2016 to December 2018. Patients were grouped based on MN-FH or non-MN-FH. The clinical and pathological features of the patients were analyzed by χ2 test.
ResultsAmong 417 breast cancer patients, 67(16.1%) cases had MN-FH. Compared with non-MN-FH group, MN-FH group had higher proportion of vascular thrombosis (P=0.046), lymph node metastasis (P=0.023), ER negative (P=0.025), PR negative (P=0.031) and HER2 positive (P=0.041). In the further subgroup analysis, compared with non-MN-FH patients, patients with breast cancer history had higher tumor stage (P=0.011) and the tumors were more likely to be triple-negative and HER2-positive (P=0.010). Breast cancer patients with family history of other malignant tumors had higher proportion of vascular thrombosis (P=0.036) and lymph node metastasis (P=0.034).
ConclusionBreast cancer patients with MN-FH have higher degree than non-MN-FH patients. For people with MN-FH, physical examination is very important.
-
Competing interests: The authors declare that they have no competing interests.作者贡献曹欣华：数据收集、数据分析、论文撰写韩丽飞：数据收集吕建鑫：论文修改胡浩霖、张亚男：论文审阅
-
表 1 有无MN-FH的乳腺癌患者一般临床特征比较
Table 1 Comparison of clinicopathological features between breast cancer patients with or without MN-FH
下载: 导出CSV
表 2 MN-FH与乳腺癌患者临床病理特征的关系
Table 2 Relation between MN-FH and clinicopathological features of breast cancer patients
下载: 导出CSV
-
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
[2] Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101, 986 women without the disease[J]. Lancet, 2001, 358(9291): 1389-1399. doi: 10.1016/S0140-6736(01)06524-2
[3] Yoenny PG, Maikel MG, Diamela AC, et al. Risk Factors for Breast Cancer in the Female Population[J]. Finlay, 2017, 7(4): 283-289.
[4] Chikman B, Davidson T, Kais H, et al. Is there an association between invasive lobular carcinoma of the breast and a family history of gastric cancer?[J]. Fam Cancer, 2016, 15(4): 41-47. http://europepmc.org/abstract/MED/26358115
[5] Arpino G, Pensabene M, Condello C, et al. Tumor characteristics and prognosis in familial breast cancer[J]. BMC Cancer, 2016, 16(1): 924-932. doi: 10.1186/s12885-016-2962-1
[6] Suat B, Cihad T. Predictive factors affecting axillary lymph node metastasis in breast cancer[J]. Haseki Tip Bulteni-Medical Bulletin of Haseki, 2019, 57(4): 356-361. doi: 10.4274/haseki.galenos.2019.4983
[7] Zhao Y, Wang X, Huang Y, et al. Conversion of immunohisto-chemical markers conversion and breast density is associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy[J]. Cancer Manag Res, 2019, 11: 5677-5690. doi: 10.2147/CMAR.S198844
[8] Sobočan M, Turk M, Čater P, et al. Clinical features and their effect on outcomes of patients with triple negative breast cancer with or without lymph node involvement[J]. J Int Med Res, 2019, 11: 300060519887259. http://www.researchgate.net/publication/337891292_Clinical_features_and_their_effect_on_outcomes_of_patients_with_triple_negative_breast_cancer_with_or_without_lymph_node_involvement
[9] Gujam FJ, Going JJ, Edwards J, et al. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer[J]. Crit Rev Oncol Hemat, 2014, 89(2): 231-241. doi: 10.1016/j.critrevonc.2013.08.014
[10] 陈晓芬.家族性乳腺癌的临床病理特征及BRCA1/2突变的初步探讨[D].广州医科大学, 2018. Chen XF. The clinicopathologic characteristic and BRCA1/2 mutation in familial breast cancer[D]. Guangzhou Medical University, 2018.
[11] Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes[J]. Biochim Biophys Acta, 2015, 1856(1): 73-85.
[12] 王璟, 芦文丽, 王媛, 等.中国女性肿瘤家族史与乳腺癌发病风险关系的meta分析[J].中国妇幼保健, 2012, 27(7): 1105-1109. http://www.cnki.com.cn/Article/CJFDTotal-ZFYB201207068.htm Wang J, Lu WL, Wang Y, et al. Meta-analysis on the relationship between family history of tumor and the risk of breast cancer among Chinese Women[J]. Zhongguo Fu You Bao Jian, 2012, 27(7): 1105-1109. http://www.cnki.com.cn/Article/CJFDTotal-ZFYB201207068.htm
[13] 邓伟伟, 吴军, 霍怡杉, 等. BRCA基因突变对乳腺癌预后影响的meta分析[J].国际检验医学杂志, 2019, 40(17): 2058-2065. http://www.cnki.com.cn/Article/CJFDTotal-GWSQ201917003.htm Deng WW, Wu J, Huo YS, et al. BRCA gene mutation and its prognostic implication in breast carcinoma:a meta-analysis[J]. Guo Ji Jian Yan Yi Xue Za Zhi, 2019, 40(17): 2058-2065. http://www.cnki.com.cn/Article/CJFDTotal-GWSQ201917003.htm
[14] 赵翠翠, 刘红.年轻乳腺癌的分子生物学发病机制[J].肿瘤防治研究, 2020, 47(3): 213-217. doi: 10.3971/j.issn.1000-8578.2020.19.1130 Zhao CC, Liu H. Molecular biological pathogenesis of young breast cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2020, 47(3): 213-217. doi: 10.3971/j.issn.1000-8578.2020.19.1130
计量
- 文章访问数: 2190
- HTML全文浏览量: 502
- PDF下载量: 1029
